Search company, investor...
EXACT Therapeutics company logo

EXACT Therapeutics

Founded Year




Total Raised


Date of IPO


About EXACT Therapeutics

EXACT Therapeutics (FRA: 56F) is a clinical-stage biopharmaceutical company developing Acoustic Cluster Therapy (ACT), an ultrasound-mediated technology platform for targeted therapeutic enhancement. ACT is an approach to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications, including within oncology (chemotherapy and immunotherapy), infectious diseases, and neurological conditions. EXACT Therapeutics was formerly known as Phoenix Solutions. It was founded in 2012 and is based in Oslo, Norway.

Headquarters Location

Østre Aker vei 19

Oslo, 0581,


Missing: EXACT Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: EXACT Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing EXACT Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EXACT Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

EXACT Therapeutics Patents

EXACT Therapeutics has filed 2 patents.

The 3 most popular patent topics include:

  • Drug delivery devices
  • Clusters of differentiation
  • Dosage forms
patents chart

Application Date

Grant Date


Related Topics



Drug delivery devices, Prodrugs, Dosage forms, Pharmacokinetics, Nanoparticles


Application Date


Grant Date


Related Topics

Drug delivery devices, Prodrugs, Dosage forms, Pharmacokinetics, Nanoparticles



Latest EXACT Therapeutics News

EXACT Therapeutics : to present at the ABGSC Life Science Summit - May 31, 2023

May 31, 2023

05/31/2023 | 07:04am EDT Message : 31 May EXACT CEO Per Walday will present the company and the unique technology behind ACT® at 14.00 CET. The presentation will be available after the meeting on EXACT Therapeutics website; About EXACT-Tx EXACT-Tx is a clinical-stage Norwegian precision health company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and brain diseases.

EXACT Therapeutics Frequently Asked Questions (FAQ)

  • When was EXACT Therapeutics founded?

    EXACT Therapeutics was founded in 2012.

  • Where is EXACT Therapeutics's headquarters?

    EXACT Therapeutics's headquarters is located at Østre Aker vei 19, Oslo.

  • What is EXACT Therapeutics's latest funding round?

    EXACT Therapeutics's latest funding round is IPO.

  • How much did EXACT Therapeutics raise?

    EXACT Therapeutics raised a total of $1.9M.

  • Who are the investors of EXACT Therapeutics?

    Investors of EXACT Therapeutics include Investinor, Research Council of Norway, GE Healthcare and TRK Group.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.